AUTL Autolus Therapeutics plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUTL

Price (delayed)

$1.66

Market cap

$441.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$678.52M

?
Relative Growth: Rel. Growth: 69
Relative Strength: Rel. Strength: 44
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 7

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a ...

Highlights
Autolus Therapeutics's gross margin has surged by 95% YoY and by 60% QoQ
The company's gross profit has surged by 51% QoQ and by 49% YoY
Autolus Therapeutics's equity has shrunk by 71% YoY and by 39% QoQ
Autolus Therapeutics's quick ratio has decreased by 49% YoY and by 8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.autolus.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of AUTL

AUTL stock price

How has the Autolus Therapeutics stock price performed over time
Intraday
2.47%
1 week
-6.21%
1 month
5.73%
1 year
-20.57%
YTD
-16.58%
QTD
20.29%

Financial performance

How have Autolus Therapeutics's revenue and profit performed over time
Revenue
$92.62M
Gross profit
-$10.36M
Operating income
-$264.3M
Net income
-$288.97M
Gross margin
-11.2%
Net margin
-312%
Autolus Therapeutics's gross margin has surged by 95% YoY and by 60% QoQ
AUTL's operating margin has surged by 90% year-on-year and by 20% since the previous quarter
AUTL's net margin has soared by 88% year-on-year and by 18% since the previous quarter
The company's gross profit has surged by 51% QoQ and by 49% YoY

Price vs fundamentals

How does AUTL's price correlate with its fundamentals

Growth

What is Autolus Therapeutics's growth rate over time

Valuation

What is Autolus Therapeutics stock price valuation
P/E
N/A
P/B
4.06
P/S
4.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.33
The EPS has declined by 24% year-on-year
AUTL's price to book (P/B) is 80% higher than its 5-year quarterly average of 2.2 and 65% higher than its last 4 quarters average of 2.4
Autolus Therapeutics's equity has shrunk by 71% YoY and by 39% QoQ
AUTL's price to sales (P/S) is 96% lower than its 5-year quarterly average of 125.6 and 53% lower than its last 4 quarters average of 9.9
Autolus Therapeutics's revenue has increased by 23% from the previous quarter

Efficiency

How efficient is Autolus Therapeutics business performance
The return on equity has dropped by 144% year-on-year and by 30% since the previous quarter
The return on sales has surged by 90% year-on-year and by 18% since the previous quarter
Autolus Therapeutics's return on assets has shrunk by 56% YoY and by 9% QoQ
Autolus Therapeutics's ROIC has increased by 13% YoY but it has decreased by 8% from the previous quarter

Dividends

What is AUTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUTL.

Financial health

How did Autolus Therapeutics financials performed over time
The company's total assets is 26% higher than its total liabilities
Autolus Therapeutics's quick ratio has decreased by 49% YoY and by 8% QoQ
AUTL's current ratio is down by 37% year-on-year and by 2.4% since the previous quarter
The company's debt to equity has surged by 72% QoQ
Autolus Therapeutics's equity has shrunk by 71% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.